Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications
Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation Strategies.
Journal: Current oncology (Toronto, Ont.)
Published: December 27, 2025
Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 08, 2025
Real-World Treatment Patterns, Health Outcomes, and Healthcare Resource Use in Advanced Common EGFR-Positive Non-Small Cell Lung Cancer Patients Treated with Osimertinib in Alberta.
Journal: Current oncology (Toronto, Ont.)
Published: May 28, 2024
A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas.
Journal: Investigational new drugs
Published: April 29, 2024
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 12, 2022
Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade.
Journal: Clinical lung cancer
Published: July 28, 2022
Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort.
Journal: Current oncology (Toronto, Ont.)
Published: January 31, 2022
Expected Cost Savings From Low-Dose Computed Tomography Scan Screening for Lung Cancer in Alberta, Canada.
Journal: JTO clinical and research reports
Published: January 21, 2022
Novel, First-in-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-Cell Lymphoma.
Journal: Current oncology (Toronto, Ont.)
Published: January 19, 2022
Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Journal: EJHaem
Published: November 08, 2021
Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma.
Journal: EJHaem
Published: November 05, 2021
Last Updated: 09/26/2026